Phase II trials of cardiac imaging agent BFPET underway

01/3/2013 | Yahoo

FluoroPharma said Phase II trials of its BFPET imaging agent for chronic coronary artery disease have started at Massachusetts General Hospital. In this current study, the fluorine-18-labeled tracer will be compared with Rb-82 and/or other SPECT agents such as sestamibi.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN